drugset / Trial / NCT02212015
Evaluation of Votrient in Angiosarcoma
Phase 2
Terminated
26 enrolled
Heidelberg University
Hannover Medical School · collabHelios Klinikum Berlin-Buch · collabKlinikum der Universitaet Muenchen, Grosshadern · collabMedical University Innsbruck · collabMedical University of Graz · collabMedical University of Vienna · collabNovartis Pharmaceuticals · collabUniversity Hospital Dresden · collabUniversity Hospital, Essen · collabUniversitätsklinikum Hamburg-Eppendorf · collabUniversitätsmedizin Mannheim · collab
NaSingle-groupOpen-labelTreatment
Summary
Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.
Timeline
- Start
- 2014-07
- Primary completion
- 2019-12-31
- Completion
- 2020-07-01
Outcome
Outcome not reported
Stopped: “Due to interim analysis' results and definitions fixed in protocol”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |